东诚药业
(002675)
| 流通市值：96.57亿 | | | 总市值：107.12亿 |
| 流通股本：7.43亿 | | | 总股本：8.25亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 626,367,330.36 | 2,741,074,183.83 | 2,043,088,592.83 | 1,383,711,882.86 |
| 营业收入 | 626,367,330.36 | 2,741,074,183.83 | 2,043,088,592.83 | 1,383,711,882.86 |
| 二、营业总成本 | 577,283,980.83 | 2,521,698,364.08 | 1,862,700,437.32 | 1,268,737,113.89 |
| 营业成本 | 293,568,778.03 | 1,344,048,919.3 | 1,016,318,392.9 | 739,484,518.19 |
| 税金及附加 | 10,021,758.48 | 40,708,365.67 | 31,244,288.06 | 19,338,967.15 |
| 销售费用 | 102,709,578 | 417,851,759.37 | 323,232,350.7 | 206,446,290.18 |
| 管理费用 | 86,712,342.98 | 339,484,459.54 | 238,172,124.25 | 155,470,979.34 |
| 研发费用 | 42,012,466.91 | 232,610,637.05 | 162,333,434.08 | 94,745,266.76 |
| 财务费用 | 42,259,056.43 | 146,994,223.15 | 91,399,847.33 | 53,251,092.27 |
| 其中:利息费用 | 36,484,179.49 | 137,539,244.37 | 93,763,320.4 | 12,553,563.68 |
| 其中:利息收入 | 1,275,905.06 | 5,168,514.42 | 3,982,686.78 | 2,155,873.13 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 178,641.1 | 904,860.26 | 684,997.25 | 610,065.75 |
| 加:投资收益 | 1,470,353.07 | -16,781,001.75 | -10,265,375.8 | -6,374,584.07 |
| 资产处置收益 | 45,305.36 | 82,376.19 | 198,317.89 | 194,231.24 |
| 信用减值损失(新) | -8,116,445.88 | -15,055,905.42 | -7,751,062.9 | -7,556,002.72 |
| 其他收益 | 5,923,391.91 | 24,112,615.7 | 19,193,543.08 | 11,766,564.02 |
| 四、营业利润 | 48,584,595.09 | 212,638,764.73 | 182,448,575.03 | 113,615,043.19 |
| 加:营业外收入 | 186,707.22 | 1,942,325.89 | 1,684,247.53 | 98,657.47 |
| 减:营业外支出 | 365,165.28 | 3,138,515.04 | 2,467,526.96 | 1,625,248.02 |
| 五、利润总额 | 48,406,137.03 | 211,442,575.58 | 181,665,295.6 | 112,088,452.64 |
| 减:所得税费用 | 13,538,964.54 | 57,001,304.47 | 57,110,205.82 | 42,049,138.94 |
| 六、净利润 | 34,867,172.49 | 154,441,271.11 | 124,555,089.78 | 70,039,313.7 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 34,867,172.49 | 154,441,271.11 | 124,555,089.78 | 70,039,313.7 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 33,435,403.61 | 195,628,901.18 | 149,115,907.27 | 88,652,457.27 |
| 少数股东损益 | 1,431,768.88 | -41,187,630.07 | -24,560,817.49 | -18,613,143.57 |
| 扣除非经常损益后的净利润 | 29,927,987.91 | 179,562,546.01 | 133,693,446.36 | 80,469,519.66 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.04 | 0.24 | 0.18 | 0.11 |
| (二)稀释每股收益 | 0.04 | 0.24 | 0.18 | 0.11 |
| 八、其他综合收益 | -15,147,336.34 | -566,212.92 | -1,998,026.56 | 1,813,407.68 |
| 归属于母公司股东的其他综合收益 | -12,055,768.3 | -3,027,658.79 | -4,315,783.19 | -327,958.84 |
| 九、综合收益总额 | 19,719,836.15 | 153,875,058.19 | 122,557,063.22 | 71,852,721.38 |
| 归属于母公司股东的综合收益总额 | 21,379,635.31 | 192,601,242.39 | 144,800,124.08 | 88,324,498.43 |
| 归属于少数股东的综合收益总额 | -1,659,799.16 | -38,726,184.2 | -22,243,060.86 | -16,471,777.05 |
| 公告日期 | 2026-04-28 | 2026-03-26 | 2025-10-29 | 2025-08-15 |
| 审计意见(境内) | | 标准无保留意见 | | |